文献速递肝病消化道肿瘤与早癌

转录组分析鉴定TIGIT为肝癌T细胞耗竭的标志物

Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
PubMed 文献 · Hepatology · 2021-01-01

研究通过小鼠自发性肝癌模型比较初始、功能性效应和耗竭肿瘤特异性CD8 T细胞的转录组,发现抑制性免疫受体TIGIT上调是T细胞耗竭的标志,且比PD-1更可靠地识别不同分化阶段的耗竭CD8 T细胞;TIGIT拮抗抗体联合PD-1抑制可协同抑制肝癌生长;肝癌和肝内胆管癌患者肿瘤浸润CD8 T细胞表达TIGIT,并据此分为两个亚群。

要点

  • TIGIT上调是肝癌T细胞耗竭的标志,比PD-1更可靠识别耗竭CD8 T细胞。
  • TIGIT拮抗抗体联合PD-1抑制在免疫健全小鼠中协同抑制肝癌生长。
  • 肝癌和肝内胆管癌患者肿瘤浸润CD8 T细胞表达TIGIT,可据此分两个亚群。

核心结论

  • 转录组分析为识别肝癌T细胞耗竭关键通路提供资源,并将TIGIT确定为检查点联合治疗的潜在靶点。

研究设计与样本

  • 研究对小鼠自发性肝癌模型中初始、功能性效应和耗竭肿瘤特异性CD8 T细胞进行mRNA转录组分析,并功能验证所鉴定基因在T细胞耗竭中的作用。

主要发现

  • 耗竭T细胞具有独特转录组特征,抑制性免疫受体TIGIT上调是肝癌T细胞耗竭过程的标志。
  • 与PD-1相比,TIGIT表达更可靠地识别不同分化阶段的耗竭CD8 T细胞。
  • 在免疫健全小鼠中,TIGIT拮抗抗体联合PD-1抑制协同抑制肝癌生长。
  • 肝细胞癌和肝内胆管癌患者肿瘤浸润CD8 T细胞表达TIGIT,并基于肿瘤特异性T细胞TIGIT差异表达分为两个亚群。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Programmed death 1 (PD-1) checkpoint inhibition has shown promising results in patients with hepatocellular carcinoma, inducing objective responses in approximately 20% of treated patients. The roles of other coinhibitory molecules and their individual contributions to T-cell dysfunction in liver cancer, however, remain largely elusive. APPROACH AND RESULTS: We performed a comprehensive mRNA profiling of cluster of differentiation 8 (CD8) T cells in a murine model of autochthonous liver cancer by comparing the transcriptome of naive, functional effector, and exhausted, tumor-specific CD8 T cells. Subsequently, we functionally validated the role of identified genes in T-cell exhaustion. Our results reveal a unique transcriptome signature of exhausted T cells and demonstrate that up-regulation of the inhibitory immune receptor T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitor motif domains (TIGIT) represents a hallmark in the process of T-cell exhaustion in liver cancer. Compared to PD-1, expression of TIGIT more reliably identified exhausted CD8 T cells at different stages of their differentiation. In combination with PD-1 inhibition, targeting of TIGIT with antagonistic antibodies resulted in synergistic inhibition of liver cancer growth in immunocompetent mice. Finally, we demonstrate expression of TIGIT on tumor-infiltrating CD8 T cells in tissue samples of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma and identify two subsets of patients based on differential expression of TIGIT on tumor-specific T cells. CONCLUSIONS: Our transcriptome analysis provides a valuable resource for the identification of key pathways involved in T-cell exhaustion in patients with liver cancer and identifies TIGIT as a potential target in checkpoint combination therapies.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Ostroumov D, Duong S, Wingerath J, et al. Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer. Hepatology. 2021. PMID: 32716559. doi:10.1002/hep.31466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。